Redhill Biopharma (RDHL) Competitors $1.70 +0.18 (+11.84%) Closing price 09/17/2025 03:56 PM EasternExtended Trading$1.70 +0.01 (+0.29%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. BIVI, FLGC, NXTC, TRAW, TXMD, SNGX, LGVN, BCDA, LPTX, and PHIOShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include BioVie (BIVI), Flora Growth (FLGC), NextCure (NXTC), Traws Pharma (TRAW), TherapeuticsMD (TXMD), Soligenix (SNGX), Longeveron (LGVN), BioCardia (BCDA), Leap Therapeutics (LPTX), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors BioVie Flora Growth NextCure Traws Pharma TherapeuticsMD Soligenix Longeveron BioCardia Leap Therapeutics Phio Pharmaceuticals Redhill Biopharma (NASDAQ:RDHL) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk. Do analysts prefer RDHL or BIVI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has more risk & volatility, RDHL or BIVI? Redhill Biopharma has a beta of 4.25, suggesting that its share price is 325% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Do insiders and institutionals hold more shares of RDHL or BIVI? 7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 2.4% of BioVie shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to RDHL or BIVI? In the previous week, Redhill Biopharma had 1 more articles in the media than BioVie. MarketBeat recorded 1 mentions for Redhill Biopharma and 0 mentions for BioVie. BioVie's average media sentiment score of 0.00 beat Redhill Biopharma's score of -1.00 indicating that BioVie is being referred to more favorably in the news media. Company Overall Sentiment Redhill Biopharma Negative BioVie Neutral Is RDHL or BIVI more profitable? Redhill Biopharma's return on equity of 0.00% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets Redhill BiopharmaN/A N/A N/A BioVie N/A -89.02%-75.32% Which has higher valuation and earnings, RDHL or BIVI? Redhill Biopharma has higher revenue and earnings than BioVie. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedhill Biopharma$9.55M0.41-$8.27MN/AN/ABioVieN/AN/A-$17.54M-$79.10-0.02 SummaryRedhill Biopharma beats BioVie on 8 of the 11 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.49M$2.53B$5.74B$10.30BDividend YieldN/A59.99%5.86%4.62%P/E RatioN/A23.2976.8026.52Price / Sales0.41486.45448.8087.93Price / CashN/A169.8537.2260.63Price / Book-0.465.2914.066.31Net Income-$8.27M$32.95M$3.29B$271.37M7 Day Performance6.25%-1.29%-0.77%0.57%1 Month Performance18.06%3.50%3.84%6.20%1 Year Performance-82.56%-3.48%87.65%28.33% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$1.70+11.8%N/A-83.6%$3.49M$9.55M0.00210Negative NewsShort Interest ↑High Trading VolumeBIVIBioVie0.1823 of 5 stars$1.80+3.4%N/A-93.8%$13.11MN/A-0.0210FLGCFlora Growth3.2919 of 5 stars$23.59+4.8%$93.00+294.2%-34.1%$13.02M$59.51M-0.69280News CoveragePositive NewsShort Interest ↓NXTCNextCure4.6263 of 5 stars$4.85flat$25.50+425.8%-66.5%$12.98MN/A-0.1990Short Interest ↓TRAWTraws Pharma1.562 of 5 stars$1.86+3.9%N/AN/A$12.64M$230K0.0217Short Interest ↓Gap DownTXMDTherapeuticsMD1.4778 of 5 stars$1.08flatN/A-38.4%$12.50M$1.76M0.00420Short Interest ↓SNGXSoligenix2.5364 of 5 stars$2.66-7.0%$6.00+125.6%-22.4%$12.26MN/A-0.7020Positive NewsShort Interest ↓LGVNLongeveron3.2728 of 5 stars$0.85+7.4%$7.67+802.0%-62.6%$12.02M$2.39M-0.1420BCDABioCardia3.4285 of 5 stars$2.09+1.5%$25.00+1,096.2%-45.0%$11.95M$60K-1.1340News CoverageGap UpLPTXLeap Therapeutics2.5995 of 5 stars$0.29+1.0%$3.38+1,080.5%-88.8%$11.73MN/A-0.1840PHIOPhio Pharmaceuticals2.7936 of 5 stars$2.12+3.9%$14.00+560.4%-42.9%$11.68MN/A-0.6510News CoverageShort Interest ↓ Related Companies and Tools Related Companies BioVie Competitors Flora Growth Competitors NextCure Competitors Traws Pharma Competitors TherapeuticsMD Competitors Soligenix Competitors Longeveron Competitors BioCardia Competitors Leap Therapeutics Competitors Phio Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
